Gyre Therapeutics (NASDAQ:GYRE) Announces Quarterly Earnings Results

Key Points

• Gyre Therapeutics reported a $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by $0.01, with a net margin of 7.20% and a return on equity of 9.73%.
• Following the earnings announcement, Gyre Therapeutics' stock decreased by 1.7%, trading at $7.07, with a market cap of $662.88 million.
• Bank of America Corp DE increased its stake in Gyre Therapeutics by 40.4%, further indicating institutional interest as approximately 24% of the stock is held by institutional investors.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) posted its earnings results on Monday. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01), Zacks reports. Gyre Therapeutics had a net margin of 7.20% and a return on equity of 9.73%.

Gyre Therapeutics Stock Down 1.7%

Gyre Therapeutics stock traded down $0.12 during trading hours on Monday, hitting $7.07. The stock had a trading volume of 75,208 shares, compared to its average volume of 79,807. The stock has a market cap of $662.88 million, a price-to-earnings ratio of 353.68 and a beta of 1.80. Gyre Therapeutics has a one year low of $6.11 and a one year high of $19.00. The business's 50 day simple moving average is $7.67 and its 200-day simple moving average is $9.20.

Hedge Funds Weigh In On Gyre Therapeutics

A hedge fund recently raised its stake in Gyre Therapeutics stock. Bank of America Corp DE increased its holdings in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) by 40.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,937 shares of the company's stock after purchasing an additional 1,996 shares during the period. Bank of America Corp DE's holdings in Gyre Therapeutics were worth $84,000 at the end of the most recent quarter. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.